Advertisement

Topics

Dainippon Sumitomo Pharma America, Inc. Company Profile

12:51 EST 21st November 2017 | BioPortfolio

Dainippon Sumitomo Pharma America, Inc. (DSPA) located in Fort Lee, N.J., is a subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP). On April 1, 2010, DSP's two North American operations - DSPA and Sepracor Inc. - will merge, with Sepracor Inc. surviving as the company's U.S. headquarters and the Fort Lee location will remain a satellite office.


News Articles [970 Associated News Articles listed on BioPortfolio]

Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda(Lurasidone Hydrochloride) in Europe

TOKYO and ROME, November 21, 2017 /PRNewswire/ -- Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada; hereinafter "Sumitomo Dainippon Pharma") and Angelini S.p....

Sumitomo Dainippon Pharma Co., Ltd. Strategy, SWOT and Corporate Finance Report [Report Updated: 02082017] Prices from USD $175

Sumitomo Dainippon Pharma Co., Ltd. Strategy, SWOT and Corporate Finance ReportSummarySumitomo Dainippon Pharma Co., Ltd. Strategy, SWOT and Corporate Finance Report, is a source of comprehensive co...

Sumitomo Dainippon seeks new indication for PD drug in Japan

Tokyo’s Sumitomo Dainippon Pharma has applied to extend its Japanese marketing authorization for Parkinson’s…

Sumitomo Dainippon gains Japan and other Asian rights to imeglimin

Sumitomo Dainippon Pharma has entered into a strategic collaboration with French diabetes-focused biotech…

Sumitomo Dainippon gets rights to Poxel's imeglimin in thirteen Asian countries

Poxel SA licensed Sumitomo Dainippon Pharma Co. Ltd. rights to develop and commercialize its Phase II Type II diabetes candidate imeglimin in Japan, China, South Korea, Taiwan, Indonesia, Vietnam, Tha...

Sumitomo Dainippon Pharma Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 18102017] Prices from USD $350

Sumitomo Dainippon Pharma Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Sumitomo Dainippon Pharma Co., Ltd. Mergers Acquisitions MA, Partnershi...

Sumitomo Dainippon Pharma Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 14062017] Prices from USD $350

Sumitomo Dainippon Pharma Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Sumitomo Dainippon Pharma Co., Ltd. Mergers Acquisitions MA, Partnershi...

Sumitomo Dainippon Cancer Stemness Inhibitor Napabucasin Disappoints in Phase III

Sumitomo Dainippon Pharma is unblinding the global Phase III BRIGHTER study evaluating its cancer stemness inhibitor napabucasin (BBI-608) in patients with gastric and gastro-esophageal junction (GEJ)...

Drugs and Medications [463 Associated Drugs and Medications listed on BioPortfolio]

Antimicrobial [Safetec of America]

Antimicrobial

A.b.h.c. instant hand sanitizer citrus scent [Safetec of America, Inc.]

A.B.H.C. INSTANT HAND SANITIZER

Hydrocortisone [Safetec of America, Inc.]

Safetec First Aid 1% Hydrocortisone Cream

Analgesic [Safetec of America, Inc.]

Safetec of America, Inc. PAIN SPRAY

Antiseptic [Safetec of America]

ANTISEPTIC – Benzalkonium chloride liquid Safetec of America

PubMed Articles [532 Associated PubMed Articles listed on BioPortfolio]

Lurasidone: Efficacy and Safety in the Treatment of Psychotic and Mood Disorders.

Lurasidone ([3aR,4S,7R,7aS]-2-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1yl-methyl] cyclohexylmethyl]-hexahydro-4,7-methano-2H-isoindole-1,3-dione hydrochloride; Latuda® [LRSD]) is a novel ben...

Delivering advanced therapies: The big pharma approach.

After two decades of focused development and some recent clinical successes, cell and gene therapy (CGT) is emerging as a promising approach to personalized medicines. Genetically engineered cells as ...

Bioanalytical outsourcing: transitioning from Pharma to CRO.

Clinical Trials Series - Large Pharma.

AI-powered drug discovery captures pharma interest.

Clinical Trials [381 Associated Clinical Trials listed on BioPortfolio]

A Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed Release (DR) Capsules (Takeda Pharmaceuticals America Inc., USA)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Dexlansoprazole from Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant...

Improving Perinatal Care in Latin America

Many obstetrical interventions used in Latin America, as in other parts of the world, have been shown to be ineffective or harmful, while effective interventions remain underutilized. This...

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia

This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA). The purpose of this study is to evaluate the effectiveness of secondary prophylacti...

Companies [1612 Associated Companies listed on BioPortfolio]

Dainippon Sumitomo Pharma America, Inc.

Dainippon Sumitomo Pharma America, Inc. (DSPA) located in Fort Lee, N.J., is a subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP). On April 1, 2010, DSP's two North American operations - DSPA and...

Dainippon Sumitomo Pharma Co., Ltd.

Dainippon Sumitomo Pharma Co., Ltd., (DSP), is a top-ten listed pharmaceutical company in Japan with a diverse portfolio of pharmaceutical, animal health and food and specialty products. DSP's strong...

Chelsea Therapeutics International, Ltd.

Chelsea Therapeutics (Nasdaq:CHTP) is a biopharmaceutical development company that acquires, develops and commercializes innovative products for the treatment of a variety of huma...

Sumitomo Corporation of America (SCOA)

Sumitomo Corporation of America (SCOA) brings a global perspective to today's business opportunities as the largest subsidiary of Sumitomo Corporation (SC), one of Japan's major integrated trading and...

Sumitomo Corporation of America

Sumitomo Corporation of America (SCOA) is a wholly owned subsidiary of Sumitomo Corporation (SC), an integrated trading and investment enterprise engaged in multifaceted business activities, which inc...

More Information about "Dainippon Sumitomo Pharma America, Inc." on BioPortfolio

We have published hundreds of Dainippon Sumitomo Pharma America, Inc. news stories on BioPortfolio along with dozens of Dainippon Sumitomo Pharma America, Inc. Clinical Trials and PubMed Articles about Dainippon Sumitomo Pharma America, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Dainippon Sumitomo Pharma America, Inc. Companies in our database. You can also find out about relevant Dainippon Sumitomo Pharma America, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record